_id
691483f7ccc777a4e85d94b7
Ticker
NRXPW
Name
NRx Pharmaceuticals Inc
Exchange
NASDAQ
Address
1201 Orange Street, Wilmington, DE, United States, 19801
Country
USA
Sector
Industry
Currency
USD
Website
https://www.nrxpharma.com
Description
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Last Close
0.1602
Volume
537
Current Price
0.0582
Change
-0.0028
Last Updated
2026-01-05T11:40:44.936Z
Image
data:image/webp;base64,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
Ipo Date
2017-12-01T00:00:00.000Z
Market Cap
714611100
Next Dividend Date
-
Dividend Frequency
-
Dividend Rate
-
Dividend Yield
0
Sentiment
-
Sentiment Sources
0
Current Quarter
2025-09-30
Revenue
242000
Cost Of Revenue
97000
Gross Profit
145000
Operating Expenses
4169000
Operating Income
-4024000
Interest Expense
0
Pretax Income
-5890000
Net Income
-5890000
Eps
-0.2649432252307997
Dividends Per Share
-
Shares Outstanding
0
Income Tax Expense
-
EBITDA
-5847000
Operating Margin
-1662.8099173553717
Total Other Income Expense Net
-1866000
Cash
7184000
Short Term Investments
-
Receivables
239000
Inventories
-
Total Current Assets
11947000
Property Plant Equipment
350000
Total Assets
14996000
Payables
4257000
Short Term Debt
189000
Long Term Debt
-
Total Liabilities
40751000
Equity
-25755000
Bs_currency_symbol
USD
Depreciation
41000
Change In Working Capital
567000
Cash From Operations
-2891000
Capital Expenditures
0
Cash From Investing
-2561000
Cash From Financing
9726000
Net Change In Cash
4274000
Cf_currency_symbol
USD
PE
-
PB
-0.05023702425160163
ROE
22.869345758105222
ROA
-39.27714057081889
FCF
-2891000
Fcf Percent
-11.946280991735538
Piotroski FScore
1
Health Score
31
Deep Value Investing Score
0.5
Defensive Investing Score
7
Dividend Investing Score
1.5
Economic Moat Investing Score
6.3
Garp Investing Score
2
Growth Investing Score
1.5
Momentum Investing Score
3.5
Net Net Investing Score
0.5
Quality Investing Score
2
Value Investing Score
2.5
Quarters > 0 > quarter
2025-09-30
Quarters > 0 > income Statement > revenue
242000
Quarters > 0 > income Statement > cost Of Revenue
97000
Quarters > 0 > income Statement > gross Profit
145000
Quarters > 0 > income Statement > operating Expenses
4169000
Quarters > 0 > income Statement > operating Income
-4024000
Quarters > 0 > income Statement > interest Expense
0
Quarters > 0 > income Statement > pretax Income
-5890000
Quarters > 0 > income Statement > net Income
-5890000
Quarters > 0 > income Statement > eps
-0.2649432252307997
Quarters > 0 > income Statement > dividends Per Share
-
Quarters > 0 > income Statement > shares Outstanding
22231178
Quarters > 0 > income Statement > income Tax Expense
-
Quarters > 0 > income Statement > EBITDA
-5847000
Quarters > 0 > income Statement > operating Margin
-1662.8099173553717
Quarters > 0 > income Statement > total Other Income Expense Net
-1866000
Quarters > 0 > income Statement > currency_symbol
USD
Quarters > 0 > balance Sheet > cash
7184000
Quarters > 0 > balance Sheet > short Term Investments
-
Quarters > 0 > balance Sheet > receivables
239000
Quarters > 0 > balance Sheet > inventories
-
Quarters > 0 > balance Sheet > total Current Assets
11947000
Quarters > 0 > balance Sheet > property Plant Equipment
350000
Quarters > 0 > balance Sheet > total Assets
14996000
Quarters > 0 > balance Sheet > payables
4257000
Quarters > 0 > balance Sheet > short Term Debt
189000
Quarters > 0 > balance Sheet > long Term Debt
-
Quarters > 0 > balance Sheet > total Liabilities
40751000
Quarters > 0 > balance Sheet > equity
-25755000
Quarters > 0 > balance Sheet > currency_symbol
USD
Quarters > 0 > cash Flow > net Income
-5890000
Quarters > 0 > cash Flow > depreciation
41000
Quarters > 0 > cash Flow > change In Working Capital
567000
Quarters > 0 > cash Flow > cash From Operations
-2891000
Quarters > 0 > cash Flow > capital Expenditures
0
Quarters > 0 > cash Flow > cash From Investing
-2561000
Quarters > 0 > cash Flow > cash From Financing
9726000
Quarters > 0 > cash Flow > net Change In Cash
4274000
Quarters > 0 > cash Flow > currency_symbol
USD
Quarters > 0 > ratios > PE
-0.2649432252307997
Quarters > 0 > ratios > PB
-0.05023702425160163
Quarters > 0 > ratios > ROE
22.869345758105222
Quarters > 0 > ratios > ROA
-39.27714057081889
Quarters > 0 > ratios > FCF
-2891000
Quarters > 0 > ratios > Piotroski FScore
1
Quarters > 0 > ratios > fcf Percent
-11.946280991735538
Quarters > 0 > health Score
31
Quarters > 1 > quarter
2025-06-30
Quarters > 1 > income Statement > revenue
0
Quarters > 1 > income Statement > cost Of Revenue
-
Quarters > 1 > income Statement > gross Profit
-
Quarters > 1 > income Statement > operating Expenses
3730000
Quarters > 1 > income Statement > operating Income
-3730000
Quarters > 1 > income Statement > interest Expense
0
Quarters > 1 > income Statement > pretax Income
-17581000
Quarters > 1 > income Statement > net Income
-17581000
Quarters > 1 > income Statement > eps
-0.9803060031238646
Quarters > 1 > income Statement > dividends Per Share
-
Quarters > 1 > income Statement > shares Outstanding
17934196
Quarters > 1 > income Statement > income Tax Expense
-
Quarters > 1 > income Statement > EBITDA
-17581000
Quarters > 1 > income Statement > operating Margin
-
Quarters > 1 > income Statement > total Other Income Expense Net
-13851000
Quarters > 1 > income Statement > currency_symbol
USD
Quarters > 1 > balance Sheet > cash
2910000
Quarters > 1 > balance Sheet > short Term Investments
-
Quarters > 1 > balance Sheet > receivables
-
Quarters > 1 > balance Sheet > inventories
-
Quarters > 1 > balance Sheet > total Current Assets
4590000
Quarters > 1 > balance Sheet > property Plant Equipment
-
Quarters > 1 > balance Sheet > total Assets
4838000
Quarters > 1 > balance Sheet > payables
3630000
Quarters > 1 > balance Sheet > short Term Debt
10232000
Quarters > 1 > balance Sheet > long Term Debt
-
Quarters > 1 > balance Sheet > total Liabilities
40453000
Quarters > 1 > balance Sheet > equity
-35615000
Quarters > 1 > balance Sheet > currency_symbol
USD
Quarters > 1 > cash Flow > net Income
-17580000
Quarters > 1 > cash Flow > depreciation
0
Quarters > 1 > cash Flow > change In Working Capital
-516000
Quarters > 1 > cash Flow > cash From Operations
-4028000
Quarters > 1 > cash Flow > capital Expenditures
0
Quarters > 1 > cash Flow > cash From Investing
-
Quarters > 1 > cash Flow > cash From Financing
1390000
Quarters > 1 > cash Flow > net Change In Cash
-2638000
Quarters > 1 > cash Flow > currency_symbol
USD
Quarters > 1 > ratios > PE
-0.9803060031238646
Quarters > 1 > ratios > PB
-0.029307039371051523
Quarters > 1 > ratios > ROE
49.36403200898498
Quarters > 1 > ratios > ROA
-363.39396444811905
Quarters > 1 > ratios > FCF
-4028000
Quarters > 1 > ratios > Piotroski FScore
1
Quarters > 1 > ratios > fcf Percent
-
Quarters > 1 > health Score
39
Quarters > 2 > quarter
2025-03-31
Quarters > 2 > income Statement > revenue
4000
Quarters > 2 > income Statement > cost Of Revenue
2000
Quarters > 2 > income Statement > gross Profit
2000
Quarters > 2 > income Statement > operating Expenses
3847000
Quarters > 2 > income Statement > operating Income
-3847000
Quarters > 2 > income Statement > interest Expense
0
Quarters > 2 > income Statement > pretax Income
-5512000
Quarters > 2 > income Statement > net Income
-5512000
Quarters > 2 > income Statement > eps
-0.3358927483241926
Quarters > 2 > income Statement > dividends Per Share
-
Quarters > 2 > income Statement > shares Outstanding
16410000
Quarters > 2 > income Statement > income Tax Expense
-
Quarters > 2 > income Statement > EBITDA
-5512000
Quarters > 2 > income Statement > operating Margin
-96175
Quarters > 2 > income Statement > total Other Income Expense Net
-1665000
Quarters > 2 > income Statement > currency_symbol
USD
Quarters > 2 > balance Sheet > cash
5548000
Quarters > 2 > balance Sheet > short Term Investments
-
Quarters > 2 > balance Sheet > receivables
-
Quarters > 2 > balance Sheet > inventories
-
Quarters > 2 > balance Sheet > total Current Assets
7256000
Quarters > 2 > balance Sheet > property Plant Equipment
-
Quarters > 2 > balance Sheet > total Assets
7590000
Quarters > 2 > balance Sheet > payables
4311000
Quarters > 2 > balance Sheet > short Term Debt
8397000
Quarters > 2 > balance Sheet > long Term Debt
-
Quarters > 2 > balance Sheet > total Liabilities
32751000
Quarters > 2 > balance Sheet > equity
-25161000
Quarters > 2 > balance Sheet > currency_symbol
USD
Quarters > 2 > cash Flow > net Income
-5512000
Quarters > 2 > cash Flow > depreciation
1000
Quarters > 2 > cash Flow > change In Working Capital
548000
Quarters > 2 > cash Flow > cash From Operations
-3480000
Quarters > 2 > cash Flow > capital Expenditures
0
Quarters > 2 > cash Flow > cash From Investing
-
Quarters > 2 > cash Flow > cash From Financing
7585000
Quarters > 2 > cash Flow > net Change In Cash
4105000
Quarters > 2 > cash Flow > currency_symbol
USD
Quarters > 2 > ratios > PE
-0.3358927483241926
Quarters > 2 > ratios > PB
-0.037958030284964826
Quarters > 2 > ratios > ROE
21.906919438814036
Quarters > 2 > ratios > ROA
-72.62187088274045
Quarters > 2 > ratios > FCF
-3480000
Quarters > 2 > ratios > Piotroski FScore
1
Quarters > 2 > ratios > fcf Percent
-870
Quarters > 2 > health Score
31
Quarters > 3 > quarter
2024-12-31
Quarters > 3 > income Statement > revenue
4000
Quarters > 3 > income Statement > cost Of Revenue
1000
Quarters > 3 > income Statement > gross Profit
-1000
Quarters > 3 > income Statement > operating Expenses
3633000
Quarters > 3 > income Statement > operating Income
-3634000
Quarters > 3 > income Statement > interest Expense
0
Quarters > 3 > income Statement > pretax Income
-9078000
Quarters > 3 > income Statement > net Income
-9078000
Quarters > 3 > income Statement > eps
-0.8631739089093848
Quarters > 3 > income Statement > dividends Per Share
-
Quarters > 3 > income Statement > shares Outstanding
10517000
Quarters > 3 > income Statement > income Tax Expense
-
Quarters > 3 > income Statement > EBITDA
-9077000
Quarters > 3 > income Statement > operating Margin
-90850
Quarters > 3 > income Statement > total Other Income Expense Net
-5444000
Quarters > 3 > income Statement > currency_symbol
USD
Quarters > 3 > balance Sheet > cash
1443000
Quarters > 3 > balance Sheet > short Term Investments
-
Quarters > 3 > balance Sheet > receivables
-
Quarters > 3 > balance Sheet > inventories
-
Quarters > 3 > balance Sheet > total Current Assets
3302000
Quarters > 3 > balance Sheet > property Plant Equipment
-
Quarters > 3 > balance Sheet > total Assets
3651000
Quarters > 3 > balance Sheet > payables
4130000
Quarters > 3 > balance Sheet > short Term Debt
1566000
Quarters > 3 > balance Sheet > long Term Debt
5011000
Quarters > 3 > balance Sheet > total Liabilities
26874000
Quarters > 3 > balance Sheet > equity
-23223000
Quarters > 3 > balance Sheet > currency_symbol
USD
Quarters > 3 > cash Flow > net Income
-9078000
Quarters > 3 > cash Flow > depreciation
1000
Quarters > 3 > cash Flow > change In Working Capital
-86000
Quarters > 3 > cash Flow > cash From Operations
-2098000
Quarters > 3 > cash Flow > capital Expenditures
0
Quarters > 3 > cash Flow > cash From Investing
-
Quarters > 3 > cash Flow > cash From Financing
1895000
Quarters > 3 > cash Flow > net Change In Cash
-203000
Quarters > 3 > cash Flow > currency_symbol
USD
Quarters > 3 > ratios > PE
-0.8631739089093848
Quarters > 3 > ratios > PB
-0.026357033974938642
Quarters > 3 > ratios > ROE
39.09055677561039
Quarters > 3 > ratios > ROA
-248.6442070665571
Quarters > 3 > ratios > FCF
-2098000
Quarters > 3 > ratios > Piotroski FScore
1
Quarters > 3 > ratios > fcf Percent
-524.5
Quarters > 3 > health Score
31
Annuals > 0 > quarter
2024-12-31
Annuals > 0 > income Statement > revenue
0
Annuals > 0 > income Statement > cost Of Revenue
5000
Annuals > 0 > income Statement > gross Profit
-5000
Annuals > 0 > income Statement > operating Expenses
19699000
Annuals > 0 > income Statement > operating Income
-19704000
Annuals > 0 > income Statement > interest Expense
1079000
Annuals > 0 > income Statement > pretax Income
-25126000
Annuals > 0 > income Statement > net Income
-25126000
Annuals > 0 > income Statement > eps
-2.389084339640582
Annuals > 0 > income Statement > dividends Per Share
-
Annuals > 0 > income Statement > shares Outstanding
10517000
Annuals > 0 > income Statement > income Tax Expense
-
Annuals > 0 > income Statement > EBITDA
-24042000
Annuals > 0 > income Statement > operating Margin
-
Annuals > 0 > income Statement > total Other Income Expense Net
-5422000
Annuals > 0 > income Statement > currency_symbol
USD
Annuals > 0 > balance Sheet > cash
1443000
Annuals > 0 > balance Sheet > short Term Investments
-
Annuals > 0 > balance Sheet > receivables
-
Annuals > 0 > balance Sheet > inventories
-
Annuals > 0 > balance Sheet > total Current Assets
3302000
Annuals > 0 > balance Sheet > property Plant Equipment
-
Annuals > 0 > balance Sheet > total Assets
3651000
Annuals > 0 > balance Sheet > payables
4130000
Annuals > 0 > balance Sheet > short Term Debt
1566000
Annuals > 0 > balance Sheet > long Term Debt
5011000
Annuals > 0 > balance Sheet > total Liabilities
26874000
Annuals > 0 > balance Sheet > equity
-23223000
Annuals > 0 > balance Sheet > currency_symbol
USD
Annuals > 0 > cash Flow > net Income
-25126000
Annuals > 0 > cash Flow > depreciation
5000
Annuals > 0 > cash Flow > change In Working Capital
5291000
Annuals > 0 > cash Flow > cash From Operations
-10637000
Annuals > 0 > cash Flow > capital Expenditures
0
Annuals > 0 > cash Flow > cash From Investing
-
Annuals > 0 > cash Flow > cash From Financing
7485000
Annuals > 0 > cash Flow > net Change In Cash
-3152000
Annuals > 0 > cash Flow > currency_symbol
USD
Annuals > 0 > ratios > PE
-2.389084339640582
Annuals > 0 > ratios > PB
-0.03079515997071869
Annuals > 0 > ratios > ROE
108.19446238642725
Annuals > 0 > ratios > ROA
-688.1950150643659
Annuals > 0 > ratios > FCF
-10637000
Annuals > 0 > ratios > Piotroski FScore
0
Annuals > 0 > ratios > fcf Percent
-
Annuals > 0 > health Score
30
Annuals > 1 > quarter
2023-12-31
Annuals > 1 > income Statement > revenue
0
Annuals > 1 > income Statement > cost Of Revenue
5000
Annuals > 1 > income Statement > gross Profit
-5000
Annuals > 1 > income Statement > operating Expenses
27582000
Annuals > 1 > income Statement > operating Income
-27587000
Annuals > 1 > income Statement > interest Expense
120000
Annuals > 1 > income Statement > pretax Income
-30150000
Annuals > 1 > income Statement > net Income
-30150000
Annuals > 1 > income Statement > eps
-3.9796726504751847
Annuals > 1 > income Statement > dividends Per Share
-
Annuals > 1 > income Statement > shares Outstanding
7576000
Annuals > 1 > income Statement > income Tax Expense
-9000
Annuals > 1 > income Statement > EBITDA
-30025000
Annuals > 1 > income Statement > operating Margin
-
Annuals > 1 > income Statement > total Other Income Expense Net
-2563000
Annuals > 1 > income Statement > currency_symbol
USD
Annuals > 1 > balance Sheet > cash
4595000
Annuals > 1 > balance Sheet > short Term Investments
-
Annuals > 1 > balance Sheet > receivables
6000
Annuals > 1 > balance Sheet > inventories
-6000
Annuals > 1 > balance Sheet > total Current Assets
6884000
Annuals > 1 > balance Sheet > property Plant Equipment
-
Annuals > 1 > balance Sheet > total Assets
7315000
Annuals > 1 > balance Sheet > payables
4632000
Annuals > 1 > balance Sheet > short Term Debt
9161000
Annuals > 1 > balance Sheet > long Term Debt
-
Annuals > 1 > balance Sheet > total Liabilities
19048000
Annuals > 1 > balance Sheet > equity
-11733000
Annuals > 1 > balance Sheet > currency_symbol
USD
Annuals > 1 > cash Flow > net Income
-30150000
Annuals > 1 > cash Flow > depreciation
5000
Annuals > 1 > cash Flow > change In Working Capital
5164000
Annuals > 1 > cash Flow > cash From Operations
-21657000
Annuals > 1 > cash Flow > capital Expenditures
3000
Annuals > 1 > cash Flow > cash From Investing
-3000
Annuals > 1 > cash Flow > cash From Financing
6201000
Annuals > 1 > cash Flow > net Change In Cash
-15459000
Annuals > 1 > cash Flow > currency_symbol
USD
Annuals > 1 > ratios > PE
-3.9796726504751847
Annuals > 1 > ratios > PB
-0.04390761101167647
Annuals > 1 > ratios > ROE
256.96752748657633
Annuals > 1 > ratios > ROA
-412.1667805878333
Annuals > 1 > ratios > FCF
-21660000
Annuals > 1 > ratios > Piotroski FScore
0
Annuals > 1 > ratios > fcf Percent
-
Annuals > 1 > health Score
30
Annuals > 2 > quarter
2022-12-31
Annuals > 2 > income Statement > revenue
0
Annuals > 2 > income Statement > cost Of Revenue
4000
Annuals > 2 > income Statement > gross Profit
-4000
Annuals > 2 > income Statement > operating Expenses
44331000
Annuals > 2 > income Statement > operating Income
-44335000
Annuals > 2 > income Statement > interest Expense
4581000
Annuals > 2 > income Statement > pretax Income
-39754000
Annuals > 2 > income Statement > net Income
-39754000
Annuals > 2 > income Statement > eps
-0.6044672860249061
Annuals > 2 > income Statement > dividends Per Share
-
Annuals > 2 > income Statement > shares Outstanding
65767000
Annuals > 2 > income Statement > income Tax Expense
-4581000
Annuals > 2 > income Statement > EBITDA
-39750000
Annuals > 2 > income Statement > operating Margin
-
Annuals > 2 > income Statement > total Other Income Expense Net
4581000
Annuals > 2 > income Statement > currency_symbol
USD
Annuals > 2 > balance Sheet > cash
20054000
Annuals > 2 > balance Sheet > short Term Investments
-
Annuals > 2 > balance Sheet > receivables
7000
Annuals > 2 > balance Sheet > inventories
-7000
Annuals > 2 > balance Sheet > total Current Assets
25795000
Annuals > 2 > balance Sheet > property Plant Equipment
-
Annuals > 2 > balance Sheet > total Assets
25816000
Annuals > 2 > balance Sheet > payables
2076000
Annuals > 2 > balance Sheet > short Term Debt
7703000
Annuals > 2 > balance Sheet > long Term Debt
2822000
Annuals > 2 > balance Sheet > total Liabilities
18407000
Annuals > 2 > balance Sheet > equity
7409000
Annuals > 2 > balance Sheet > currency_symbol
USD
Annuals > 2 > cash Flow > net Income
-39754000
Annuals > 2 > cash Flow > depreciation
4000
Annuals > 2 > cash Flow > change In Working Capital
699000
Annuals > 2 > cash Flow > cash From Operations
-39755000
Annuals > 2 > cash Flow > capital Expenditures
10000
Annuals > 2 > cash Flow > cash From Investing
-10000
Annuals > 2 > cash Flow > cash From Financing
32214000
Annuals > 2 > cash Flow > net Change In Cash
-7551000
Annuals > 2 > cash Flow > currency_symbol
USD
Annuals > 2 > ratios > PE
-0.6044672860249061
Annuals > 2 > ratios > PB
0.6036112835740316
Annuals > 2 > ratios > ROE
-536.5636388176542
Annuals > 2 > ratios > ROA
-153.98977378370003
Annuals > 2 > ratios > FCF
-39765000
Annuals > 2 > ratios > Piotroski FScore
1
Annuals > 2 > ratios > fcf Percent
-
Annuals > 2 > health Score
20
Annuals > 3 > quarter
2021-12-31
Annuals > 3 > income Statement > revenue
0
Annuals > 3 > income Statement > cost Of Revenue
2000
Annuals > 3 > income Statement > gross Profit
-2000
Annuals > 3 > income Statement > operating Expenses
95199000
Annuals > 3 > income Statement > operating Income
-95201000
Annuals > 3 > income Statement > interest Expense
18000
Annuals > 3 > income Statement > pretax Income
-93063000
Annuals > 3 > income Statement > net Income
-93063000
Annuals > 3 > income Statement > eps
-1.9835244469073703
Annuals > 3 > income Statement > dividends Per Share
-
Annuals > 3 > income Statement > shares Outstanding
46918000
Annuals > 3 > income Statement > income Tax Expense
-21348000
Annuals > 3 > income Statement > EBITDA
-93043000
Annuals > 3 > income Statement > operating Margin
-
Annuals > 3 > income Statement > total Other Income Expense Net
2138000
Annuals > 3 > income Statement > currency_symbol
USD
Annuals > 3 > balance Sheet > cash
27605000
Annuals > 3 > balance Sheet > short Term Investments
-
Annuals > 3 > balance Sheet > receivables
0
Annuals > 3 > balance Sheet > inventories
-
Annuals > 3 > balance Sheet > total Current Assets
32714000
Annuals > 3 > balance Sheet > property Plant Equipment
-
Annuals > 3 > balance Sheet > total Assets
32729000
Annuals > 3 > balance Sheet > payables
3687000
Annuals > 3 > balance Sheet > short Term Debt
518000
Annuals > 3 > balance Sheet > long Term Debt
-
Annuals > 3 > balance Sheet > total Liabilities
11923000
Annuals > 3 > balance Sheet > equity
20806000
Annuals > 3 > balance Sheet > currency_symbol
USD
Annuals > 3 > cash Flow > net Income
-93063000
Annuals > 3 > cash Flow > depreciation
2000
Annuals > 3 > cash Flow > change In Working Capital
-4898000
Annuals > 3 > cash Flow > cash From Operations
-37703000
Annuals > 3 > cash Flow > capital Expenditures
7000
Annuals > 3 > cash Flow > cash From Investing
-7000
Annuals > 3 > cash Flow > cash From Financing
63456000
Annuals > 3 > cash Flow > net Change In Cash
25746000
Annuals > 3 > cash Flow > currency_symbol
USD
Annuals > 3 > ratios > PE
-1.9835244469073703
Annuals > 3 > ratios > PB
0.1533415360953571
Annuals > 3 > ratios > ROE
-447.28924348745556
Annuals > 3 > ratios > ROA
-284.3441596137981
Annuals > 3 > ratios > FCF
-37710000
Annuals > 3 > ratios > Piotroski FScore
0
Annuals > 3 > ratios > fcf Percent
-
Annuals > 3 > health Score
29
Valuation > metrics > PE
-0.2649432252307997
Valuation > metrics > PB
-0.05023702425160163
Valuation > final Score
50
Valuation > verdict
Fair
Profitability > metrics > ROE
22.869345758105222
Profitability > metrics > ROA
-49.30107976897966
Profitability > metrics > Net Margin
-24.33884297520661
Profitability > final Score
40
Profitability > verdict
Weak
Risk > metrics > Interest Coverage
-93.5813953488372
Risk > final Score
-344
Risk > verdict
High
Liquidity > metrics > Current Ratio
2.6871345029239766
Liquidity > metrics > Quick Ratio
2.6871345029239766
Liquidity > final Score
100
Liquidity > verdict
Great
Prev Valuations > 0
50
Prev Valuations > 1
50
Prev Valuations > 2
50
Prev Profitabilities > 0
55
Prev Profitabilities > 1
40
Prev Profitabilities > 2
40
Prev Risks > 0
50
Prev Risks > 1
50
Prev Risks > 2
-14506
Prev Liquidities > 0
27
Prev Liquidities > 1
39
Prev Liquidities > 2
39
Updated At
2026-01-20T22:18:19.812Z
Earnings History > 0 > period
2021-06-30
Earnings History > 0 > report Date
2021-09-30
Earnings History > 0 > date
2021-06-30
Earnings History > 0 > before After Market
-
Earnings History > 0 > currency
USD
Earnings History > 0 > eps Actual
-0.4015
Earnings History > 0 > eps Estimate
0
Earnings History > 0 > eps Difference
-0.4015
Earnings History > 0 > surprise Percent
-
Earnings History > 1 > period
2021-03-31
Earnings History > 1 > report Date
2021-06-30
Earnings History > 1 > date
2021-03-31
Earnings History > 1 > before After Market
-
Earnings History > 1 > currency
USD
Earnings History > 1 > eps Actual
-6.5144
Earnings History > 1 > eps Estimate
0
Earnings History > 1 > eps Difference
-6.5144
Earnings History > 1 > surprise Percent
-
Earnings History > 2 > period
2020-12-31
Earnings History > 2 > report Date
2021-03-31
Earnings History > 2 > date
2020-12-31
Earnings History > 2 > before After Market
-
Earnings History > 2 > currency
USD
Earnings History > 2 > eps Actual
-2.2588
Earnings History > 2 > eps Estimate
0
Earnings History > 2 > eps Difference
-2.2588
Earnings History > 2 > surprise Percent
-
Earnings History > 3 > period
2020-06-30
Earnings History > 3 > report Date
2020-09-30
Earnings History > 3 > date
2020-06-30
Earnings History > 3 > before After Market
-
Earnings History > 3 > currency
USD
Earnings History > 3 > eps Actual
-0.1512
Earnings History > 3 > eps Estimate
0
Earnings History > 3 > eps Difference
-0.1512
Earnings History > 3 > surprise Percent
-
Earnings History > 4 > period
2020-03-31
Earnings History > 4 > report Date
2020-06-30
Earnings History > 4 > date
2020-03-31
Earnings History > 4 > before After Market
-
Earnings History > 4 > currency
USD
Earnings History > 4 > eps Actual
0.0028
Earnings History > 4 > eps Estimate
0
Earnings History > 4 > eps Difference
0.0028
Earnings History > 4 > surprise Percent
-
Earnings History > 5 > period
2019-12-31
Earnings History > 5 > report Date
2020-03-31
Earnings History > 5 > date
2019-12-31
Earnings History > 5 > before After Market
-
Earnings History > 5 > currency
USD
Earnings History > 5 > eps Actual
-0.1487
Earnings History > 5 > eps Estimate
0
Earnings History > 5 > eps Difference
-0.1487
Earnings History > 5 > surprise Percent
-
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Stock Price
$0.00
decrease compared to yesterday.
Dividend
Frequency:
Rate:
N/ANext Payout:
N/AAug Update: Does aTyr Pharma Inc. have pricing power - Market Risk Analysis & Fast Gain Swing Alerts baoquankhu1.vn
Read more →Breakouts Watch: What is the earnings history of SHCO - July 2025 Weekly Recap & Real-Time Buy Signal Notifications baoquankhu1.vn
Read more →Showing 2 of 6
(Last Updated 2025-09-30)
Health Score
Price to Book Ratio (P/B)
-
Very Low
Low ≤ 1
High ≥ 3
Return on Equity (ROE)
-
Very High
Low ≤ 5%
High ≥ 25%
Return on Assets (ROA)
-
Very Low
Low ≤ 2%
High ≥ 10%
Free Cash Flow - Revenue % (FCF)
-
Very Low
Low ≤ 5%
High ≥ 15%
* Institutions hold a combined 0.00% of the total shares of NRx Pharmaceuticals Inc
* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.
Date
—
EPS Estimate
—
Date
2021-06-30
EPS Actual
-0.4015
EPS Estimate
0
EPS Difference
-0.4015
Surprise Percent
0%
(Last Updated 2025-09-30)
(Last Updated 2025-09-30)
Revenue
$ 0
Cost Of Revenue
$ 0
Gross Profit
$ 0
Operating Expenses
$ 0
Operating Income
$ 0
Interest Expense
$ 0
Pretax Income
$ 0
Net Income
$ 0
Income Tax Expense
$ 0
EBITDA
$ 0
Total Other Income Expense Net
$ 0
Earnings Per Share
0
Dividends Per Share
0
Shares Outstanding
0
Operating Margin
0%
(Last Updated 2025-09-30)
Cash
$ 0
Short Term Investments
$ 0
Receivables
$ 0
Inventories
$ 0
Total Current Assets
$ 0
Property Plant Equipment
$ 0
Total Assets
$ 0
Payables
$ 0
Short Term Debt
$ 0
Long Term Debt
$ 0
Total Liabilities
$ 0
Equity
$ 0
(Last Updated 2025-09-30)
Net Income
$ 0
Depreciation
$ 0
Change In Working Capital
$ 0
Cash From Operations
$ 0
Capital Expenditures
$ 0
Cash From Investing
$ 0
Cash From Financing
$ 0
Net Change In Cash
$ 0
Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.